Medtronic and Recor Medical each announced separate Medicare reimbursement approvals for their respective renal denervation ...

Summary of Mount Sinai's New York BCI Symposium, by Synchron and Precision Neuroscience. Market Trends and forecast for brain ...

and neurological disorders, while its top clients are hospitals, healthcare providers, and government healthcare programs. The most recent quarter saw Medtronic increase its total revenue by 5.3% YoY.

ClearPoint Neuro reported strong YoY growth in Q3, but the stock reacted negatively. Check out my recommendation for CLPT ...

ClearPoint Neuro develops and commercializes platforms for performing minimally invasive surgical procedures in the brain.

Q3 2024 Earnings Call Transcript November 7, 2024 ClearPoint Neuro, Inc. misses on earnings expectations. Reported EPS is $-0.18 EPS, expectations were $-0.17. Operator: Greetings, and welcome to the ...

Integra Lifesciences today announced it named Mojdeh Poul as president and CEO, effective January 6, 2025.

About a year ago, renal denervation procedures won a huge victory after finally being greenlit by FDA. Now two of the frontrunners in the space have received reimbursement.

Medtronic plc added a second U.S. FDA pulsed field ablation (PFA) device approval to its scorecard with the agency’s greenlight for its Affera mapping and ablation system with the Sphere-9 catheter.

Medtronic MDT underwent analysis by 15 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table provides a quick overview of their recent ...

Medtronic has issued a second alert letter to patients regarding shortened battery life of the MiniMed 600 and 700 series insulin pumps. The affected products include the MiniMed 630G, 670G, 770G ...